Stifel Financial’s HTG Molecular Diagnostics HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-318
Closed -$96K – 3006
2019
Q2
$96K Sell
318
-828
-72% -$345K ﹤0.01% 2826
2019
Q1
$526K Buy
1,146
+211
+23% +$92.4K ﹤0.01% 2033
2018
Q4
$429K Sell
935
-167
-15% -$104K ﹤0.01% 2025
2018
Q3
$1.01M Buy
1,102
+162
+17% +$107K ﹤0.01% 1657
2018
Q2
$550K Buy
940
+416
+79% +$271K ﹤0.01% 1981
2018
Q1
$343K Buy
+524
New +$393K ﹤0.01% 2173

Other funds holding HTGM

Stifel Financial's HTGM Position: Q3 2019 in Review

Stifel Financial sold out of HTG Molecular Diagnostics (HTGM) in Q3 2019, closing a stake of 318 shares — an estimated $96K sold.

Stifel Financial first reported a position in HTGM in Q1 2018 and held it in 6 quarters. The position peaked at $1.01M in Q3 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

  • Stifel Financial reported no remaining HTG Molecular Diagnostics position as of Q3 2019 after selling out during the quarter.
  • Stifel Financial sold 318 HTG Molecular Diagnostics shares in Q3 2019, an estimated $96K.
  • Stifel Financial first reported a position in HTG Molecular Diagnostics in Q1 2018 and held it in 6 quarters.
  • Stifel Financial's HTG Molecular Diagnostics position peaked at $1.01M in Q3 2018.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics as of Q3 2019.

Based on Stifel Financial's 13F filing for Q3 2019, filed 13 Nov 2019.